Optune Gio
Novocure, GmbH · Decision date Jun 4, 2026
What did the FDA approve?
FDA records P100034/S042 as a supplement to PMA P100034, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Jun 4, 2026.
FDA approval order statement
Approval for an additional manufacturing site, AvailMed S.A. de C.V., located at C. Industrial Lt. 001 Mz. 105, No. 20905 Int. A. Col. Cd. IndustrialTijuana, Baja California, Mexico, for the HFE Arrays in the Optune Gio system.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Neurology
- Decision date
- Jun 4, 2026
- FDA change category
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P100034/S042
- Regulatory pathway
- PMA supplement
- Applicant
- Novocure, GmbH
- Product code
- NZK
- Decision code
- APPR
- Decision date
- Jun 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, low electric field, tumor treatment.
- Applicant
- Novocure, GmbH
- Product code
- NZK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P100034. Subsequent supplements may change the device or its indications.
FDA decision timeline
P100034 · Original PMA
NOVOCURE LTD'S NOVOTTF-100A TREATMENT KIT
P100034/S042 received
Application receipt date recorded by FDA.
P100034/S041 · Related supplement
Optune Gio - Maxpoint Version 2.0
P100034/S043 · Related supplement
Optune Gio
P100034/S044 · Related supplement
Optune HFE Transducer Array Soft Part Components
P100034/S042 · FDA decision
Normal 180 Day Track No User Fee
P100034/S046 · Related supplement
Optune HFE Transducer Arrays
P100034/S045 · Related supplement
Novocure GmbHs Optune Gio
Timeline entries are records held by MedtechLedger for P100034. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P100034
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Novocure, GmbH | PMA approval | Apr 8, 2011 | FDA | |
Optune Gio - Maxpoint Version 2.0P100034/S041 | Novocure, GmbH | PMA supplement | Oct 23, 2025 | FDA |
Optune GioP100034/S043 | Novocure, GmbH | PMA supplement | Feb 25, 2026 | FDA |
Optune HFE Transducer Array Soft Part ComponentsP100034/S044 | Novocure, GmbH | PMA supplement | Apr 9, 2026 | FDA |
Optune HFE Transducer ArraysP100034/S046 | Novocure, GmbH | PMA supplement | Sep 16, 2026 | FDA |
Novocure GmbHs Optune GioP100034/S045 | Novocure, GmbH | PMA supplement | Sep 18, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Novocure, GmbH
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Neuhofstrasse 21, Baar, 6340
Sources and methodology
- Original FDA record: P100034/S042
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




